Figure 1E illustrated that stage IV patients with a HER2−/HoR+ status had more bone metastasis (HER2−/HoR+ vs HER2+/HoR− vs HER2+/HoR+ vs HER2−/HoR−: 79.7% vs 35.8% vs 61.0% vs 43.0%, respectively), whereas patients with a HER2+/HoR− status had an increased incidence of liver metastasis (HER2−/HoR+ vs HER2+/HoR− vs HER2+/HoR+ vs HER2−/HoR−: 8.1% vs 32.7% vs 20.3% vs 18.9%, respectively). Here, ERBB2 is linked to bone metastasis.